BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

B SUZHOU, China, May 5, 2026 /PRNewswire/ — BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as ” BrightGene Bio-Medical” or “the Company”) announced that…
posteditor
posteditor
Articles: 21727

Other News